TDSPharm Co

TDSPharm Co Net Debt per Share

The Net Debt per Share of TDSPharm Co (464280.KQ) as of Nov 5, 2026 is -5,320.15 KRW. In the previous year, Net Debt per Share was -1,785.39 KRW — a change of 197.98% (lower).

Net Debt per Share

-5,320.15KRW

YoY

197.98%

Last updated:

Net Debt per Share of TDSPharm Co is 2024 -5,320.15 KRW. Net Debt per Share of TDSPharm Co was 2023 -1,785.39 KRW. It decreases by 197.98% lower compared to the previous year.

The TDSPharm Co Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2022
-667.00 KRW
Jan 1, 2023
-1,785.39 KRW
Jan 1, 2024
-5,320.15 KRW
The TDSPharm Co Net Debt per Share history
YEARNet Debt per ShareYoY
-5,320.15KRW+197.98%
-1,785.39KRW+167.67%
-667.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Net Debt per Share of TDSPharm Co is -5,320.15 KRW in 2024.

Net Debt per Share of TDSPharm Co changed from -1,785.39 KRW to -5,320.15 KRW, representing a 197.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — TDSPharm Co

All Key Metrics — TDSPharm Co